Harnesses deep learning and synthetic biology to accelerate drug discovery and development, aiming to design better biologics.
Absci Corporation is a pioneering drug and target discovery company based in Vancouver, Washington, specializing in the provision of biologic drug candidates and production cell lines through its integrated drug creation platform. Established in 2011, Absci is at the forefront of transforming biopharmaceutical development by streamlining the drug discovery and cell line development processes into a unified workflow.
The core of Absci's innovation lies in its integrated drug creation platform, which optimizes efficiency and accelerates the timeline from discovery to production of biologics. This platform not only enhances the speed and precfision of drug development but also offers partners in the United States access to a comprehensive suite of capabilities tailored to meet the complex demands of modern biopharmaceutical research and production.
With a commitment to advancing biotechnology through cutting-edge research and strategic collaborations, Absci Corporation continues to drive forward in its mission to deliver transformative solutions for the healthcare industry. By leveraging its integrated approach and robust technological infrastructure, Absci aims to address critical challenges in drug discovery and development, ultimately improving patient outcomes worldwide.